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 ABSTRACT 
Background : 5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one 
of the most useful agents for the treatment of colorectal adenocarcinoma. Low toxicity and 
convenience of administration facilitate use, however clinical resistance is a major 
limitation. Investigation has failed to fully explain the molecular mechanisms of resistance 
and no clinically useful predictive biomarkers for 5FU resistance have been identified. We 
investigated the molecular mechanisms of clinical 5FU resistance in colorectal 
adenocarcinoma patients in a prospective biomarker discovery project utilising gene 
expression profiling. The aim was to identify novel 5FU resistance mechanisms and qualify 
these as candidate biomarkers and therapeutic targets.  
Methods : Putative treatment specific gene expression changes were identified in a 
transcriptomics study of rectal adenocarcinomas, biopsied and profiled before and after 
pre-operative short-course radiotherapy or 5FU based chemo-radiotherapy, using 
microarrays. Tumour from untreated controls at diagnosis and resection identified 
treatment-independent gene expression changes. Candidate 5FU chemo-resistant genes 
were identified  by comparison of gene expression data sets from these clinical specimens 
with gene expression signatures from our previous studies of colorectal cancer cell lines, 
where parental and daughter lines resistant to 5FU were compared.  A colorectal 
adenocarcinoma tissue microarray (n=234, resected tumours) was used as an independent 
set to qualify candidates thus identified. 
Results : APRIL/TNFSF13 mRNA  was significantly upregulated following 5FU based 
concurrent chemo-radiotherapy and in 5FU resistant colorectal adenocarcinoma cell lines 
but not in radiotherapy alone treated colorectal adenocarcinomas.  Consistent withAPRIL’s 
known function as an autocrine or paracrine secreted molecule, stromal but not tumour cell 
protein expression by immunohistochemistry was correlated with poor prognosis (p=0.019) 
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in the independent set.  Stratified analysis revealed that protein expression of APRIL in the 
tumour stroma is associated with survival in adjuvant 5FU treated patients only (n=103, 
p<0.001), and is independently predictive of lack of clinical benefit from adjuvant 5FU  
[HR 6.25 (95%CI 1.48-26.32), p=0.013].  
Conclusions :  A combined investigative model, analysing the transcriptional response in 
clinical tumour specimens and cancers cell lines, has identified APRIL, a novel chemo-
resistance biomarker with independent predictive impact in 5FU-treated CRC patients,  that 
may represent a target for novel therapeutics.  
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BACKGROUND 
Significant progress has been made recently in the systemic treatment of colorectal 
adnocarcinoma (CRC).  There are currently 8 agents licensed for use in the US and Europe 
5-fluorouracil (5FU), floxuridine, capecitabine , irinotecan, oxaliplatin, cetuximab, 
panitumumab and bevacizumab(1). Combination therapy is the standard of care for both 
early and advanced disease (1).  5FU, or an oral analogue capecitabine, is a component of 
the majority of combination regimens and the low toxicity, ease and convenience of 
administration, favour its clinical use. However, a modest response rate due to clinical 
resistance to 5FU is a major limitation. Older studies with 5FU monotherapy demonstrate 
that the majority of CRC patients treated will not benefit from 5FU, for example the 
objective response rate to 5FU or capecitabine monotherapy in advanced CRC is 20% (1). 
 Identification of the clinically important mechanisms of resistance to 5FU would allow 
better selection of patients for 5FU therapy and the rationale design of targeted therapeutics 
to overcome resistance, and thus increase the proportion of patients deriving benefit from 
5FU.  A predictive biomarker for clinical 5FU resistance would clearly be useful, but 
progress has been limited in this area and investigation has thus far failed to fully explain 
the molecular mechanisms that areimportant for clinical 5FU  resistance (2-4). Preclinical 
and clinical studies have mainly focussed upon molecules concerned with 5FU metabolism 
(Dihydropyrimidine dehydrogenase (DPD), Thymidine phosphorylase (TP)) or  
Thymidylate Synthase (TS), a well characterised 5FU target (3,4). Clinical studies  in 
colorectal cancer, assessing these molecules by a variety of techniques ( IHC, RT-PCR,  
ELISA, genotyping), while demonstrating correlation between benefit (such as response 
and survival) from 5FU or capecitabine,  have so far failed either to demonstrate genuine 
clinical utility as predictive biomarkers or produce useful targeted agents (3) .  Overall, 
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given the widespread clinical use of 5FU or its oral formulations, there is still a need for 
novel discovery approaches in this area. 
 The global perspective provided by gene expression profiling has provided novel insights 
into the molecular mechanisms of clinical response to therapy in  human cancers (5) , 
although few studies have specifically addressed clinical therapy response in colorectal 
adenocarcinomas (6-10) and only 1 has analysed serial biopsies before and after treatment 
(8). This report describes our prospectively designed discovery study, Aberdeen 
Microarray in Rectal Cancer Study-1 (AMRECS1) using a combined approach, identifying 
candidate molecules from clinical specimens and comparing them with our 5FU chemo-
resistance data from cell line model systems (11). We aimed to identify novel mechanisms 
of resistance to 5-fluorouracil (5FU) that are clinically relevant in CRC patients. Tumour 
biopsies were collected before and after pre-operative therapy in rectal cancer patients 
following staging and stratification with magnetic resonance imaging (MRI), to identify 
gene expression changes that occur following either ‘short course’ radiotherapy (SCRT) or 
5FU-based concurrent chemo-radiotherapy (CRT). Gene expression profiles from these 
matched clinical specimens were compared with profiles generated from colorectal 
adenocarcinoma cell lines, both sensitive parental and derived daughter cell lines with 
increasing resistance to 5FU. Data is presented for the validation of one potential novel 
clinical 5FU resistance candidate APRIL/TNFSF13 in an independent set of 234 patients 
with colorectal cancer. 
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METHODS 
Patients, Follow up and Treatment 
 
The study was approved by the North of Scotland Research Ethics Committee.  Patients 
provided informed consent  in accordance with the regulations and instructions  of the 
North of Scotland  Research Ethics Committee for study participation , including use and  
publication of results. Full clinicopathological details are provided in table 1 and 2 and in 
Additional File -1 . Patients were selected for either SCRT or CRT based upon MRI 
staging features (12) . All the radiotherapy was CT planned, using a 3 field technique 
(posterior and two lateral fields), multileaf collimation and with patients having a full 
bladder during the radiotherapy. Surgery was performed either the following week, for 
SCRT patients, or 6 to 8 weeks after completion of chemo-radiotherapy.   
Gene expression profiling . Tumour biopsies were collected at the time of endoscopic 
diagnosis of rectal adenocarcinoma and placed immediately into RNAlater (800µl) 
(Ambion, Austin, Texas).  Tumour biopsies collected at time of curative surgical resection 
were placed immediately into normal saline and a pathologist provided a representative 
tumour biopsy, which was placed immediately into RNAlater within 30 minutes (800µl).  
Tissues were stored in RNALater at 4o C overnight (16-18 hours), then washed in 500µl ice 
cold RNase free PBS (Ambion, Austin, TX) and snap frozen in liquid nitrogen. Long-term 
storage of tissues was at –80oC.  Before RNA extraction, histological diagnosis and 
features were confirmed by frozen section histology.  Extraction and purification of total 
RNA was performed using TRIZOL reagent (Invitrogen, Carlsbad, CA) and RNeasy 
Microkits (Qiagen, Venlo, The Netherlands), according to the manufacturer’s instructions. 
Quantification of total RNA was performed by spectrophometry (260/280 ratio 1.9 to 2.2 
for all samples). Quality of total RNA and cRNA was assessed using a BioAnalyser 2100 
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(Agilent technologies, Palo Alto, CA). Target preparation for the Affymetrix Genechips™ 
was according to manufacturer’s instructions (Affymetrix, Santa Clara, CA).  Specifically, 
4µg of total RNA was used for  reverse transcription and synthesis and amplification of 
biotin labelled cRNA using the One cycle target labelling and control reagents.  Clean-up 
of biotin-cRNA was performed with RNeasy Minikits (Qiagen, Venlo, The Netherlands).  
Fragmentation was performed using  20µg of  biotin-labelled cRNA. A hybridisation 
cocktail was prepared from 15µg which was first hybridised to Test 3 GeneChips™ to 
assess sample quality (GAPDH 3’:5’ < 3 and Actin 3’: 5’ < 3) and then to HGU133 Plus2.0 
GeneChips™ (10µg) for gene expression analysis. Procedures for hybridisation, washing, 
staining and scanning of chips were carried out according to standard protocols 
(Affymetrix, Santa Clara, CA). 
Analysis of gene expression profiling data 
Analysis of the gene expression data is described in detail in  Additional file 2 and as 
described previously (11,13). Raw data for gene expression is provided in MIAME 
complaint format in Array express, accession number E-MEXP-1901 
Immunohistochemistry  
 Description of the Tissue Microarray (TMA) is provided  in previous publications (14).  A 
total of 268 colorectal tumours and 50 normal colon cores are represented, with 1 core per 
case.  During the staining procedure 34 (13%) tumour cores were lost, leaving cores from 
234 patients available for assessment. Antigen retrieval was performed by microwaving in 
10mM citrate (pH 6.0) for 20 minutes.  An autostainer (Dakocytomation, Glostrup, 
Denmark) was used for staining the sections using a mouse monoclonal primary antibody 
for human APRIL/ TNFSF13 (1:60 dilution, Abcam, Cambridge, UK) and Chemate-
Envision detection system (Dakocytomation, Glostrup, Denmark), according to the 
 8
manufacturer’s instructions. All sections were double scored by 2 independent investigators 
who were blinded to the clinical data.  Scoring discrepancies were resolved by examination 
of sections at a double-headed microscope. Sections were scored positive or negative for 
tumour and/or stromal staining. In addition tumour staining intensity was scored as weak, 
moderate or strong. 
Statistical analysis 
Continuity corrected χ2 test, with Fisher’s exact test where appropriate, was used for binary 
categorical variables, Pearson’s χ2 test for non-binary categorical variables and Student’s t-
test for numerical variables. Kaplan-Meier curves were constructed to assess survival and 
the log rank test to assess statistical significance. The Cox proportional hazards model was 
used for multivariate analysis of survival. Two-sided p values of less than 0.05 were 
considered significant. All analyses were performed using SPSS for Windows, version 13.0 
(SPSS Inc, Chicago, IL). 
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RESULTS 
Chemo-radiotherapy or radiotherapy altered gene expression in rectal cancer  
In a pilot transcriptomics study of rectal cancer patients, we used oligonucleotide 
microarrays to profile the expression of over 47000 transcripts representing 38562 human 
genes in rectal tumour biopsies before and after pre-operative treatment with CRT (n = 4 
patients) ; table 1). Rectal tumour biopsies before and after SCRT (n = 4 patients; table 1) 
were also analysed to enable comparison of gene expression changes in patients treated 
with 5FU-based chemo-radiotherapy with those observed in patients receiving radiotherapy 
alone.  Rectal tumour biopsies, at diagnosis and surgical resection, from two patients who 
did not undergo any pre-operative treatment  (table 1) were used to identify treatment-
independent gene expression changes.  
 
SOPs were developed and validated to allow collection of tissues at endoscopic diagnosis 
and at surgical resection, whilst preserving RNA integrity.   Total RNA extracted from 
these tissues (10-30mg) in this pilot study provided sufficient yield (8 to 40 ug) and quality 
total RNA for gene expression analysis on Affymetrix oligonucleotide microarrays.  Raw 
gene expression data is provided in MIAME complaint format in Array express, accession 
number E-MEXP-1901.  
 
Threshold and probabilistic filtering of the data (see Additional file 2) identified 86 genes 
(91 probe sets) consistently, significantly and specifically altered following 5FU-based 
CRT and 51 genes (58 probe sets) following SCRT (see Additional File 3 for details of 
genes and fold change following therapy). Hierarchical cluster analysis, highlights 2 
distinct clusters of genes up-regulated or down-regulated following CRT (figure 1A) or 
SCRT (figure 1B). The expression profiles of each of these gene sets clearly separates pre- 
 10
and post-treatment samples into two primary clusters for each treatment group (figure 1). A 
matrix analysis (DMTv1.0, Affymetrix, CA) of therapy-altered gene sets identified using 
threshold filtering alone (see Additional file 2; 697 probe sets in CRT group and 570 in 
SCRT group, including 86 overlapping), reveals that these genes sets are significantly non-
overlapping (p= 0.010), demonstrating highly distinct alterations to the tumour 
transcriptome following treatment with SCRT or 5FU-based CRT.   
 
The biological functions of the CRT and SCRT altered gene sets were evaluated (additional 
file 4). While many of the same key biological pathways are identified in each treatment 
group, consistent with a co-ordinated transcriptional response, there are some pathways 
only altered following CRT and some pathways (cell death and cell cycle) where there is 
numerically significantly more change in gene expression in the CRT treated patients 
(additional file 4).   
 
This represents an initial pilot study of the first samples in our rectal cancer patient cohort. 
It is important to note that the small sample size, necessitates validation of these candidate 
gene expression changes in a larger cohort.  The primary aim of this study was to identify 
candidate 5FU resistance markers in rectal tumours, in a pilot discovery study using a 
transcriptome-wide approach and to validate key candidate/s that may have mechanistic 
relevance in a larger cohort.  Identification and validation of one such marker is described 
below.   
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APRIL/ TNFSF13 in colorectal cancer 
As we were interested in potential mediators of 5FU resistance in rectal tumours in vivo, 
we further mined the gene expression analysis using a pathway focussed analysis of cell 
deaths pathways, including those involved in regulation or execution of caspase-dependent 
apoptotic, caspase-independent and necrotic cell death genes (n=2177 genes; additional file 
5).   Threshold and probabilistic filtering of the gene expression data identified 17 cell 
death genes consistently and significantly altered in rectal tumours following chemo-
radiotherapy (additional file 6). Several of these genes have been implicated in colorectal 
cancer pathogenesis and the pathogenesis of other cancers, and also radioresistance, but 
none previously in 5FU chemoresistance (for more details see additional file 6).  
Comparison of the 17 cell death genes altered in response to 5FU based CRT in tumours 
from rectal cancer patients, with gene expression changes identified in our previous study 
of 5FU resistant cancer cell lines (11), demonstrated 4 of the 17 genes up-regulated 
following CRT (but not radiotherapy alone) in rectal cancer patients and in 5FU-resistant 
cancer cells compared to the sensitive parental lines(See additional file 6,Table S6.1).This 
included the TNF superfamily ligand, APRIL (TNFSF13). 
 
APRIL has been characterised as promoting cell survival and cell proliferation and this 
involves NFκB activation (15-19).  In addition, APRIL mRNA has been shown to be 
increased in colorectal tumours compared to normal mucosa (17). These data supported 
further investigation of a putative functional role for APRIL in clinical 5FU chemo-
resistance.  
APRIL protein expression was evaluated in 234 resected colorectal adenocarcinomas and 
50 normal colon or rectal mucosa specimens (table2). APRIL protein was not expressed in 
normal colon tissues but was, as expected, expressed in both colorectal tumour cells and 
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the tumour stroma (Table 3 and figure 2 ).Tumour cell staining was observed in the cytosol 
and membrane of tumour cells (figure 2). Stromal staining was evident in both the 
extracellular matrix and also in stromal cells (figure 2).  
 
APRIL, a putative 5FU chemo-resistance factor and predictive biomarkerin 5FU 
treated colorectal cancer patients 
We examined the relationship between APRIL protein expression and survival after 
surgical resection.  We prospectively determined that we would evaluate both tumour cell 
and tumour stromal expression of APRIL protein due to its  characterized biological 
function as a secreted autocrine and/or paracrine  molecule.  There was no significant 
relationship between APRIL protein expression in tumour cells and survival (Additional 
file 7). In contrast, expression of APRIL protein in the tumour stroma was associated with 
poor survival (n=234, p=0.019, figure 3a), including in stage III patients (n = 102, p=0.016, 
figure 3b), but was not associated with survival in Stage I or II (n=46  p=0.601 and n=86 
p= 0.440, respectively, Additional File 7).  
 
In light of our hypothesised role of APRIL in 5FU resistance, we stratified the Stage III 
patients according to whether or not they received adjuvant chemotherapy with 5FU 
following surgical resection of their primary tumour.  Stage I and II patients did not receive 
adjuvant chemotherapy in this series.Tumour stroma expression of APRIL protein is only 
associated with worse survival in those patients treated with adjuvant 5FU and there is no 
relationship with survival in Stage III patients not treated with adjuvant chemotherapy 
(n=102, p<0.001, figure 3c).  In 5FU treated Stage III patients (n=63), median survival for 
stroma positive is 36 months with predicted 5 year survival 42.0% (95% confidence 
interval 11.8% - 72.2%); median survival not yet reached for stroma negative and predicted 
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5 year survival is 85% (95% confidence intervals 71.7% -98.6%). Multivariate analysis 
confirms expression of APRIL protein in the tumour stroma as an independent prognostic 
factor in chemotherapy treated Stage III patients, with a HR of 6.25 (95% CI 1.48-26.32, 
p=0.013, table 4).  
The survival of the 5FU treated Stage III colorectal cancer patients who express APRIL 
protein in the tumour stroma parallels survival observed in Stage III patients who did not 
receive adjuvant therapy (treatment decision due to patient or physician preference), 
irrespective of APRIL protein expression (figure 3c). In contrast, the APRIL negative 
patients have an excellent predicted 5 year survival and have a clear and statistically 
significant (p< 0.001) survival benefit compared to untreated or APRIL positive 5FU 
treated patients (figure 3c).  These data suggest that APRIL has no prognostic impact in 
colorectal cancer treated by surgical resection alone, but has predictive impact for benefit 
from adjuvant 5FU in colorectal cancer patients.   
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DISCUSSION 
 
Global gene expression profiling of clinical response to therapy has provided a useful 
means for biomarker and novel target discovery in several solid tumours (5,13) .The work 
described in this paper has used and extended this experimental approach to rectal 
adenocarcinomas. The data presented constitutes an analysis from gene expression 
profiling of prospectively collected pre- and post-treatment tumour specimens from 
patients with rectal adenocarcinomas receiving pre-operative therapy. 
 
Since a small number of rectal adenocarcinomas  have been profiled (n=10),   stringent  and 
focussed analysis of the microarray data was applied to identify leads for further 
investigation. This included hypothesis-driven focus on cell death pathways and 
comparison with our previously published cell line work. . The key candidate was 
subsequently validated a in larger independent set (n=234) using a different technique 
(immunohistochemistry).   
 
The biological validity of the experimental model and the data is confirmed by the finding 
of significant alterations in the gene expression of  previously implicated molecules and 
pathways, for example p21 which has been implicated in numerous studies (20-25). The 
biological pathways identified (information 3 and 4) suggest a co-ordinated transcriptional 
response to radiotherapy- and CRT- induced cellular stress, consistent with other reports 
involving gene expression profiling in cell lines and several different cancer types  
(2,11,13,25-29) .We hypothesize that this reflects distinct biological effects of these two 
treatments. However, the possibility of effects due to time course differences in the tumour 
sampling in each group cannot be excluded. 
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A supervised analysis of cell death genes, reveals shared genes and pathways. The analysis 
supports the hypothesise that initiation of cell death is a common final pathway resulting 
from a multitude of upstream responses to the insult and resultant cellular stress of 
cytotoxic chemotherapy or radiotherapy thereby accounting for gene expression overlap 
seen.  
The majority of the genes identified in our analysis represent genes and pathways that 
have not previously been implicated  in clinical response of rectal adenocarcinoma or as 
mechanisms of action or resistance to radiotherapy or 5FU or 5FU-based CRT . This is 
consistent with the findings of other gene expression profiling studies in rectal 
adenocarcinoma or other tumour types for radiotherapy or 5FU (6,8-11,26,28-30). 
However, it is important to note that this discovery phase utilised a small sample cohort 
and the candidate gene expression changes require further validation in a lrger independent 
cohort. 
 
APRIL/TNFSF13 was found to be upregulated following CRT but not radiotherapy alone 
in rectal cancers and was also up-regulated in 5FU resistant cell lines in our previous 
studies (11).   The biological function of APRIL as a secreted molecule that has autocrine 
and paracrine functions to promote cell survival and proliferation and its previously 
documented expression in colorectal adenocarcinoma  but not normal cells outside the 
immune system, supported it’s further investigation as a novel mechanism of 5FU action 
and resistance, and as a predictive biomarker (15-19,31-35) . 
 
This study found that expression of APRIL protein in colorectal tumour stroma was 
associated with worse survival, but only in those patient’s treated with adjuvant 5FU 
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chemotherapy. This relationship was also maintained in a multivariate analysis of 
5FU chemotherapy treated Stage III colorectal adenocarcinoma patients (HR 6.25, 
1.47-26.31, p=0.013), in which the Hazard ratio compares favourably to other previously 
published putative 5FU predictive biomarkers in colorectal cancer (2-4) .  Tumour cell 
expression of APRIL was correlated with stromal staining but was not significantly 
associated with survival. Overall, APRIL appears to have no therapy independent 
prognostic impact in colorectal adenocarcinoma in this analysis.  
Within the limitations of a retrospective study, these results suggest that APRIL may 
have clinical utility as a predictive biomarker to select patients who would not benefit from 
adjuvant 5FU monotherapy.  For example, currently adjuvant 5FU is used  clinically in an 
empirical way without predictive biomarkers in stage III patients and in this paradigm  the 
majority of patients with Stage III cancers  will not benefit  from 5FU. Therefore, the  
ability to identify some of these stage III  patients who will not benefit from 5FU  has clear 
potential clinical utility in optimising and individualising clinical use of 5FU in this setting. 
An important question is whether APRIL confers cross resistance to other active agents 
used to treat colorectal cancer, especially Oxaliplatin and Irinotecan, this would be  
potentially useful to guide   5FU combination adjuvant therapy in stage III patients, but 
especially  in stage  II  patients where 5FU alone appears to have limited benefit . 
 
The data allows us to hypothesise that APRIL may provide a useful novel therapeutic 
target. Morphological examination has suggested that positively staining stromal cells 
include lymphocytes and fibroblasts, but not endothelial cells. This is consistent with 
evidence indicating that APRIL is predominantly secreted and exerts it’s effects via cell 
surface receptors, acting in a paracrine or autocrine fashion (15-19,31-35) . 
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Our data indicate that APRIL might be secreted by tumour cells or stromal cells within the 
tumour. The APRIL signalling mechanisms that may mediate tumour cell survival are not 
well characterised (32). However, in vitro work in glioma cell lines and ex vivo studies in 
BCLL, has shown that APRIL stimulates proliferation and inhibits apoptosis in response to 
a wide range of stimuli, including CD95L, TRAIL and cytotoxic drugs and survival in B-
CLL cells involves NFκB activation (15-19,31-34) . More recently it has been suggested 
that tumour infiltrating neutrophils may be an important source of APRIL production in 
solid tumours (35).   
 
 If APRIL is functional as an extracellular secreted molecule this makes it amenable to 
targeting with either a small molecule inhibitor or monoclonal antibody, as has been 
employed successfully for other targets in solid tumours e.g. bevacizumab against VEGF. 
An anti-APRIL targeted therapy may be useful in reversal of acquired 5FU resistance or in 
combination in patients whose tumours over-express the molecule. 
 
The lack of therapy independent prognostic impact suggests that an anti-APRIL 
therapy may not have anticancer activity on it’s own, but the cell survival 
promoting activity may be more generally applicable to other therapeutic cell death 
stresses. Therefore, combination of an anti-APRIL agent with agents other than 5FU may 
be active, and our cell line data also suggest that they may be active in other tumour types, 
such as breast cancer. 
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CONCLUSIONS 
In  this study we have  used  a combined investigative model, analysing the transcriptional 
response in clinical tumour specimens from rectal adenocarcinomas and cancer cell lines, 
to identify APRIL, as a  novel  5FU chemo-resistance biomarker. We have validated  its 
importance in an independent set of colorectal adenocarcinomas.  This data supports further 
investigation of the clinical utility of APRIL as a predictive biomarker for 5FU  resistance 
in colorectal adenocarcinomas and other solid tumour types and also  as a target for novel 
therapeutics aimed at reversal of clinical resistance to 5FU and its oral analogues. 
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FIGURE LEGENDS 
 
Figure 1   Hierarchical cluster analysis of chemoradiotherapy or radiotherapy treated 
tumours. This analysis  separates pre- and post-treatment biopsies using  (a) 86 genes 
identified as changed in chemoradiotherapy treated patients and (b) 51 genes identified as 
changed in short course radiotherapy treated patients.  (c) Post-treatment  tumour biopsies, 
cluster according to treatment received with  the  combined set of 137 genes, but (d) pre-
treatment tumour biopsies do not. Columns represent tumour samples and rows represent 
genes (red: up-regulated and green: down-regulated, radiotherapy [blue] or 
chemoradiotherapy [pink])  
 
Figure 2 . Immunohistochemistry for APRIL in resected colorectal adenocarcinomas. 
Staining for APRIL was seen in the tumour cells (membrane and cytosol) and stroma 
(extracellular matrix and stromal cells) of colorectal adenocarcinomas. All combinations of 
tumour cell and stromal staining were seen. Tumour cell staining could be scored weak, 
moderate and strong. Examples show strong tumour cell staining and stromal staining.  
 
Figure 3   APRIL protein expression in tumour stroma and survival of colorectal 
cancer patients.  (a). Kaplan-Meier survival plots for tumour stroma APRIL protein 
expression analysed by immunohistochemistry of 234 colorectal cancer patients following 
surgical resection.(b) Stromal staining for APRIL in Stage III patients following surgical 
resection (n=102) (c) Combined analysis of stage III patients (n = 102) stratified according 
to adjuvant therapy and tumour stroma APRIL protein. P value is log rank test. 
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TABLES AND CAPTIONS 
 
Table 1:  Locally advanced rectal adenocarcinoma patients  analysed by gene 
expression microarray. 
 
 
 
Patient 
 
 
 
Treatment1 
Stage at 
Diagnosis2 
Diagnostic 
biopsy grade & 
histology 
Diagnostic 
biopsy 
cellularity3 
Surgical biopsy 
grade & 
histology 
Surgical 
biopsy 
cellularity3 
Pathological  
stage4 
CRT1 
 
 
CRT T2N1M0 
moderately 
differentiated 
adenocarcinoma 60% 
poorly 
differentiated 
adenocarcinoma 60% T3N2 
CRT2 
 
 
CRT T3N1M0 
moderately 
differentiated 
adenocarcinoma 60% 
moderately 
differentiated 
adenocarcinoma 60% T3N1 
CRT3 
 
 
CRT T3N0M0 
moderately 
differentiated 
adenocarcinoma 60% 
moderately 
differentiated 
adenocarcinoma 50% T3N0 
CRT4 
 
 
CRT T4N1M0 
moderately 
differentiated 
adenocarcinoma 50% 
moderately 
differentiated 
adenocarcinoma 50% T2N0 
RT1 RT T2N0M0 
moderately 
differentiated 
adenocarcinoma 60% 
moderately 
differentiated 
adenocarcinoma 60% T3N0 
RT2 RT T2N1M0 
moderately 
differentiated 
adenocarcinoma 60% 
moderately 
differentiated 
adenocarcinoma 60% T2N1 
RT3 RT T2N0M0 
moderately 
differentiated 
adenocarcinoma 50% 
moderately 
differentiated 
adenocarcinoma 60% T3N2 
RT4 RT T2N0M0 
moderately 
differentiated 
adenocarcinoma 60% 
moderately 
differentiated 
adenocarcinoma 60% T3N0 
CON1 
 
 
 
None T3N1M0 
moderately 
differentiated 
adenocarcinoma 75% 
moderately 
differentiated 
adenocarcinoma 70% T3N1 
CON2 
 
 
 
None T2N1M0 
moderately 
differentiated 
adenocarcinoma 50% 
moderately 
differentiated 
adenocarcinoma 50% T3N1 
 
1
 CRT= neoadjuvant concurrent chemoradiotherapy; RT=Short course pre-operative 
radiotherapy.  2  MRI and clinical stage.  3  % Tumour versus normal cells in biopsy 
profiled.  4  Pathological stage post-preoperative therapy 
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Table 2:  Resected colorectal adenocarcinoma  patients analysed by 
immunohistochemistry for APRIL protein expression on tissue microarray 
 
 
 
 
 
 
 
 
 
 
 
 
 
1In this series 63/102 (62%) Stage III patients received adjuvant chemotherapy with 5FU.
Variable Frequency / 
median(range) 
 
Age 
71 years (22-92) 
Gender 
Male 
Female 
 
121 
113 
Histological Grade 
Poor 
Moderate 
Well 
 
27 
199 
8 
Tumour site 
Proximal colon 
Distal colon 
Rectum 
 
79 
86 
69 
Stage 
I 
II 
III (adjuvant chemotherapy)1 
     N2 
 
46 
86 
102 (63) 
48 
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Table 3: Tumour cell and stromal expression of APRIL protein in colorectal 
adenocarcinomas.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunohistochemical analysis of a rectal adenocarcinoma tissue microarray (n = 234 
tumours) demonstrated that APRIL protein was expressed in tumour cells and/ or tumour 
stroma.  Positive stromal expression was strong.  In tumour cells expressing APRIL, 
intensity was weak, moderate or strong.The number of rectal adenocarcinomas with 
positive staining for APRIL protein. Percentage of the total (n = 234) is in parentheses. 
There was a significant correlation between tumour cell and stromal expression (p=0.048). 
There was no significant association between tumour cell or stromal staining and age, 
gender, histological grade, tumour site or Duke’s stage (all p>0.20. Data not shown). 
APRIL 
Immunohistochemistry 
 
 
Tumour 
Cell  
      
Positive  
Weak 
Moderate 
Strong 
130 (55.6%) 
70 (29.9%) 
49 (20.9%) 
11  (4.7%) 
 
 Negative 
 
104 (44.4%) 
Stroma 
 
Positive 
 
Negative 
 
121 (51.7%) 
 
113 (48.3%) 
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Table 4: Multivariate analysis using Cox proportional hazards regression model for 
adjuvant chemotherapy treated Stage III patients. 
 
Variable HR 95% Confidence 
Interval 
p value 
Age 
(>70 vs <70) 
1.006 0.955-1.059 0.835 
Gender 
(Female vs Male) 
0.532 0.159-1.783 0.307 
Grade 
(poor vs moderate vs well) 
N/A N/A 0.873 
Site 
(Proximal vs Distal) 
5.015 0.695-36.191 0.110 
APRIL 
Tumour Stroma Staining 
(positive vs negative) 
6.250 1.471-26.316 0.013 
APRIL 
Tumour Cell Staining 
(positive vs negative) 
0.64 0.200-2.044 0.452 
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ADDITIONAL INFORMATION 
Additional File 1  
Title : Further details of Patients and Treatments 
Description : Clinicopathological,  selection criteria, staging and  chemotherapy and  
radiotherapy protocol details  for  patients in the study 
 
Additional File 2  
Title :  Details of analysis of Gene Expression Profiling Data  
Description : Details of quality control,  normalisation and analysis for identification of 
genes whose expression is consistently and significantly altered as a consequence of 
chemoradiotherapy or radiotherapy.  Figure S2. Schematic to illustrate bioinformatics 
analysis performed to identify genes whose expression was consistently and significantly 
altered as a result of either neoadjuvant chemoradiotherapy or short course radiotherapy 
 
Additional File 3  
Title : Details of genes  identified in analysis of rectal adenocarcinomas  
Description : Details of genes  identified in analysis of rectal adenocarcinomas  
 whose expression is consistently and significantly changed after treatment  with 
chemoradiotherapy or radiotherapy. Table S3.1-.List of 86 genes (91 probe sets) whose 
expression is consistently and significantly changed after treatment with 
chemoradiotherapy. Table S3.2 –List of 52 genes (58 probe sets) whose expression is 
consistently and significantly chaged after treatment with short course radiotherapy. 
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Additional file 4  
Title : Biological pathways altered following neoadjuvant radiotherapy or 
chemoradiotherapy in rectal tumours 
Description : The number of genes in each biological pathway whose expression was 
altered following chemoradiotherapy or radiotherapy is shown. Gene ontologies (biological 
function) were assigned according to GO, Genespring v6.1, Netaffx, EntrezGene, RefSeq 
and literature searches using Medline and ISI. Table S4 - The number of genes in each 
biological pathway whose expression was altered following chemoradiotherapy or 
radiotherapy 
 
 
Additional  File 5  
Title : Cell death gene list used for supervised gene expression analysis.   
Description :  Xcel file with list of identified  2177 genes  involved in the control, 
regulation and execution of cell death (apoptotic and non-apoptotic forms) that were 
represented on the HGU133 Plus 2.0 GeneGhip, using databases (GO, Genespring v6.1, 
RefSeq, EntrezGene) and literature searches (Medline and ISI).  
 
Additional File 6 : 
Title : Details of  Supervised analysis of Cell Death Pathways.  
Description :  Schematic representations to explain supervised bionformatic analysis of 
cell death pathways. Figure S6 Schematic illustrating the bioinformatics analysis 
performed for the supervised analysis of cell death genes. GCOSv1.2 and Genespring v6.1 
were used for the analyses. TableS6. List of Cell death genes identified in this analysis in 
CRT and SCRT treated rectal adenocarcinoma patients. 
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TableS6.1. Genes identified as candidate novel mechanisms of 5FU chemoresistance or 
sensitivity from gene expression profiling experiments of 5FU resistant colorectal and 
breast cancer cell lines 
 
Additional File 7: 
Title : Additional survival analyses for APRIL protein expression in colorectal 
adenocarcinomas  
Description: Kaplan-Meier survival plots  for APRIL protein expression in tumour cells of 
colorectal adenocarcinom patients in stage I, II and II and APRIl stroma expression in 
Stage I and II  Figure S7.1 Kaplan-Meier survival plots for APRIL immunohistochemistry 
showing no significant relationship for tumour cell protein expression and survival. All 
patients (n=234), analysed according to intensity of APRIL staining in tumour cells [weak, 
moderate or strong (b)] or positive versus negative tumour cell staining (a), or stratified 
according to  stage Dukes A/Stage I, Dukes B/Stage II and Dukes C/Stage III (c).  
Figure S7.2. Kaplan-Meier survival plots for APRIL immuno-histochemistry showing that 
positive staining in the tumour stroma shows no association with survival in Duke’s 
A/Stage I (n=46)  or B/Stage II tumours (n=86). 
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